Drug Database
Back to search

Netherlands· NL-4a591371d374

Fotivda 1340 microgram harde capsules

A tivozanib product containing tivozanibhydrochloride 1-water, registered in Netherlands by EUSA Pharma (Netherlands) B.V.. The same ATC class is registered in 10 of our 19 countries.

ATC L01EK03

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedFotivda 1340 microgram harde capsulesATCL01EK03REGISTER NO.NL-4a591371d374PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tivozanibhydrochloride 1-waterAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tivozanib is registered in 10 of 19 countries.

Countries holding a registration under ATC L01EK03 (tivozanib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search tivozanib products by name

Tivozanib · ATC L01EK03

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
TIVOZANIBHYDROCHLORIDE 1-WATER
Manufacturer
EUSA Pharma (Netherlands) B.V.
Country
Netherlands (NL)
ATC code
L01EK03
ATC class
Tivozanib
Defined daily dose
1 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/17/1215

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for tivozanib.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tivozanib against other medicinesHow interaction checks work

Tivozanib · interactions on record

7 records

  • 3 severe
  • 4 moderate

Most severe, free to view

  • PhenobarbitalN03AA02severe
  • PhenobarbitalN05CA24severe
  • Hyperici herbaN06AX25severe
  • RiociguatC02KX05moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tivozanib in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tivozanib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Fotivda
  • Liechtenstein · Fotivda
  • Norway · Fotivda

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ab58117e-2dfe-4573-b34f-d0f0da7cfec8
GET /v1/drugs/ab58117e-2dfe-4573-b34f-d0f0da7cfec8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/fotivda-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Tivozanib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp118981",
  "excipients": [
    "AMMONIA (E 527)",
    "BLAUWE INKT",
    "GELATINE (E 441)",
    "IJZEROXIDE GEEL (E 172)",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK (E 904)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "TIVOZANIBHYDROCHLORIDE 1-WATER"
  ],
  "leaflet_url": null,
  "authorised_at": "2017/08/24",
  "procedure_number": "EMEA/H/C/004131",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/17/1215",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about tivozanib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console